Targeting cholesterol crystal-induced inflammation for the secondary prevention of cardiovascular disease

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 19, Issue 1, 2014, Pages 45-52

  Nidorf, Stefan M ^a   Eikelboom, John W ^b   Thompson, Peter L ^a,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b MCMASTER UNIVERSITY   (Canada)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

atherosclerosis; heart disease; ischemic

Indexed keywords

CANAKINUMAB; CHOLESTEROL; COLCHICINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CHOLESTEROL TRANSPORT; CORONARY ARTERY DISEASE; CRYSTALLIZATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFLAMMATION; LONG TERM CARE; MACROPHAGE; NEUTROPHIL; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION;

ATHEROSCLEROSIS; HEART DISEASE; ISCHEMIC;

ANIMALS; CARDIOVASCULAR DISEASES; CHOLESTEROL; COLCHICINE; CRYSTALLIZATION; DISEASE PROGRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MACROPHAGES; MOLECULAR TARGETED THERAPY; NEUTROPHILS; PLAQUE, ATHEROSCLEROTIC; SECONDARY PREVENTION;

EID: 84890962511     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248413499972     Document Type: Review

References (106)

1. Netsky MG, Clarkson TB, Stokes D. The experimental production of arteriosclerosis response of the avian artery to intramural cholesterol and other insoluble substances. Am J Pathol. 1959 ; 35: 1081-1089
2. Rapp JH, Connor EW, Lin DS, Inahara T, Porter JM. Lipids of human atherosclerotic plaques and xanthomas: clues to the mechanism of plaque progression. J Lipid Res. 1983 ; 24 (10). 1329-1335
3. Katz SS, Small DM. Isolation and partial characterization of the lipid phases of human atherosclerotic plaques. J Biol Chem. 1980 ; 255 (20). 9753-9759
4. Guyton JR, Klemp KF. The lipid-rich core region of human atherosclerotic fibrous plaques. Prevalence of small lipid droplets and vesicles by electron microscopy. Am J Pathol. 1989 ; 134 (3). 705-717
5. Katz SS, Small DM, Smith FR, Dell RB, Goodman DS. Cholesterol turnover in lipid phases of human atherosclerotic plaque. J Lipid Res. 1982 ; 23 (5). 733-737
6. Katz SS, Shipley GG, Small DM. Physical chemistry of the lipids of human atherosclerotic lesions. demonstration of a lesion intermediate between fatty streaks and advanced plaques. J Clin Invest. 1976 ; 58 (1). 200-211
7. Small DM, Bond MG, Waugh D, Prack M, Sawyer JK. Physiocochemical and histological changes in the arterial wall of nonhuman primates during progression and regression of atherosclerosis. J Clin Invest. 1984 ; 73 (6). 1590-1605
8. Small DM. Progression and regression of atherosclerotic lesions: insights from lipid physical biochemistry. Arteriosclerosis. 1988 ; 8 (2). 103-129
9. Suhalim JL, Chung CY, Lilledahl MB, et al. Characterization of cholesterol crystals in atherosclerotic plaques using stimulated raman scattering and second-harmonic generation microscopy. Biophys J. 2012 ; 102 (8). 1988-1995
10. Lim RS, Suhalim JL, Miyazaki-Anzai S, et al. Identification of cholesterol crystals in plaques of atherosclerotic mice using hyperspectral CARS imaging. J Lipid Res. 2011 ; 52 (12). 2177-2186
11. Schroeder AP, Falk E. Vulnerable and dangerous coronary plaques. Atherosclerosis. 1995 ; 118 (suppl). S141 - S149
12. Frink RJ. Parallel cholesterol crystals: a sign of impending plaque rupture?. J Invasive Cardiol. 2010 ; 22 (9). 406-411
13. Mitroulis I, Skendros P, Ritis K. Targeting IL-1β in disease; the expanding role of NLRP3 inflammasome. Eur J Intern Med. 2010 ; 21 (3). 157-163
14. Malawista SE, Duff GW, Atkins E, Cheung HS, McCarty DJ. Crystal induced endogenous pyrogen production. a further look at gouty inflammation. Arthritis Rheum. 1985 ; 28 (9). 1039-1046
15. Kingsbury KR, Conaghan PG, McDermott MF. The role of the NLRP3 inflammasome in gout. J Inflamm Res. 2011 ; 4: 39-49
16. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006 ; 440 (7081). 237-241
17. Freigang S, Ampenberger F, Spohn G, et al. Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. Eur J Immunol. 2011 ; 41 (7). 2040-2051
18. Rajamaki K, Lappalainen J, Öörni K, et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One. 2010 ; 5 (7). e11765
19. Duewell P Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010 ; 464 (7293). 1357-1361
20. Naruko T, Ueda M, Haze K, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation. 2002 ; 106 (23). 2894-2900
21. Grebe A, Latz E. Cholesterol crystals and inflammation. Curr Rheumatol Rep. 2013 ; 15 (3). 313-320
22. Abela GS, Aziz K. Cholesterol crystals rupture biological membranes and human plaques during acute cardiovascular events - a novel insight into plaque rupture by scanning electron microscopy. Scanning. 2006 ; 28 (1). 1-10
23. Abela GS, Aziz K, Vedre A, Pathak DR, Talbott JD, Dejong J. Effect of cholesterol crystals on plaques and intima in arteries of patients with acute coronary and cerebrovascular syndromes. Am J Cardiol. 2009 ; 103 (7). 959-968
24. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995 ; 92 (3). 657-671
25. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013 ; 368 (21). 2004-2013
26. Hansson GK. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med. 2005 ; 352 (16). 1685-1695
27. Baetta R, Corsini A. Role of polymorphonuclear neutrophils in atherosclerosis: current state and future perspectives. Atherosclerosis. 2010 ; 210 (1). 1-13
28. Soehnlein O. Multiple roles for neutrophils in atherosclerosis. Circ Res. 2012 ; 110 (6). 875-888
29. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin survival study (4S). Lancet. 1994 ; 344 (8934). 1383-1389
30. Rosenson RS, Tangney CC. Anti-athero-thrombotic properties of statins implications for cardiovascular event reduction. JAMA. 1998 ; 279 (20). 1643-1650
31. Bernini F, Didoni G, Bonfadini G, Bellosta S, Fumagalli R. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages. Atherosclerosis. 1993 ; 104 (1-2). 19-26
32. Kempen HJM, Vermeer M, deWit E, Havekes LM. Vastatins inhibit cholesterol ester accumulation in human monocyte-derived macrophages. Arterioscler Thromb. 1991 ; 11 (1). 146-153
33. Abela GS, Vedre A, Janoudi A, Huang R, Durga S, Tamhane U. Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization. Am J Cardiol. 2011 ; 107 (12). 1710-1717
34. Kusunoki J, Hansoty DK, Aragane K, Fallon JT, Badimon JJ, Fisher EA. Acyl-CoA: cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2001 ; 103 (21). 2604-2609
35. Delsing DJ, Offerman EH, van Duyvenvoorde W, et al. Acyl-CoA: cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice. Circulation. 2001 ; 103 (13). 1778-1786
36. Accad M, Smith SJ, Newland DL, et al. Massive xanthomatosis in altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA: cholesterol acyltransferase 1. J Clin Invest. 2000 ; 105 (6). 711-719
37. Fazio S, Major AS, Swift LL, et al. Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. J Clin Invest. 2001 ; 107 (2). 163-171
38. Nissen SE, Tuzcu EM, Brewer HB, et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med. 2006 ; 354 (12). 1253-1263
39. Kellner-Weibel G, Jerome WG, Small DM, et al. Effects of intracellular free cholesterol accumulation on macrophage viability: a model for foam cell death. Arterioscler Thromb Vasc Biol. 1998 ; 18 (3). 423-431
40. Kellner-Weibel G, Yancey PG, Jerome WG, et al. Crystallization of free cholesterol in model macrophage foam cells. Arterioscler Thromb Vasc Biol. 1999 ; 19 (8). 1891-1898
41. Inazu A, Brown ML, Hesler CB, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 1990 ; 323 (18). 1234-1238
42. Clark RW, Sutfin TA, Ruggeri RB, et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol. 2004 ; 24 (3). 490-497
43. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000 ; 406 (6792). 203-207
44. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007 ; 357 (21). 2109-2122
45. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib was it the molecule or the mechanism?. Arterioscler Thromb Vasc Biol. 2007 ; 27 (2). 257-260
46. Remaley AT, Rothblat GH, Tall AR, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012 ; 125 (15). 1905-1919
47. Varas-Lorenzo C, Garcia Rodriguez LA, Maguire A, Castellsague J, Perez-Gutthann S. Use of oral corticosteroids and the risk of acute myocardial infarction. Atherosclerosis. 2007 ; 192 (2). 376-383
48. Busillo JM, Azzam KM, Cidlowski JA. Glucocorticoids sensitize the innate immune system through regulation of the NLRP3 inflammasome. J Biol Chem. 2011 ; 286 (44). 38703-38713
49. Fusch CS, Chan AT, Manson JE, et al. Anti-inflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation. 2006 ; 113 (12). 1578-1587
50. Solomon SD, McMurray JJ, Pfeffer MA, et al. Adenoma prevention with celecoxib (APC) study investigators. cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005 ; 352 (11). 1071-1080
51. Bolten WW. Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 2006 ; 65 (1). 7-13
52. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. AHA scientific statements use of nonsteroidal antiinflammatory drugs an update for clinicians: a scientific statement from the American heart association. Circulation. 2007 ; 115 (12). 1634-1642
53. Nuki G. Colchicine. Its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep. 2008 ; 10 (3). 218-227
54. Zemer D, Revach M, Pras M, et al. Controlled trial of colchicine in preventing attacks of familial mediterranean fever. N Engl J Med. 1974 ; 291 (18). 932-934
55. Cerquaglia C, Diaco M, Nucera G, La Regina M, Montalto M, Manna R. Pharmacological and clinical basis of treatment of familial mediterranean fever (FMF) with colchicine or analogues: an update. Curr Drug Targets Inflamm Allergy. 2005 ; 4 (1). 117-124
56. Cocco G, Chu DC, Pandol S. Colchicine in clinical medicine. a guide for internists. Eur J Int Med. 2010 ; 21 (6). 503-508
57. Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis results of the colchicine for acute pericarditis (COPE) trial. Circulation. 2005 ; 112 (13). 2012-2016
58. Imazio M, Bobbio M, Cecchi E, et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Intern Med. 2005 ; 165 (17). 1987-1991
59. Molad Y. Update on colchicine and its mechanism of action. Curr Rheumatol Rep. 2002 ; 4 (3). 252-256
60. Ben-Chetrit E, Bergmann S, Sood R. Mechanism of the anti-inflammatory effect of colchicine in rheumatic diseases: a possible new outlook through microarray analysis. Rheumatology. 2006 ; 45 (3). 274-282
61. Malawista SE, Seegmiller JE. The effect of pretreatment with colchicine on the inflammatory response to microcrystalline urate: a model for gouty inflammation. Ann Intern Med. 1965 ; 62: 648-657
62. Denko CW, Petricevic M. Modification of cholesterol crystal-induced inflammation. Agents Actions. 1980 ; 10 (4). 353-357
63. Cavallero C, Turolla E, Ricevuti G. Cell proliferation in the atherosclerotic plaques of cholesterol-fed rabbits. 1. colchicine and (3H)thymidine studies. Atherosclerosis. 1971 ; 13 (1). 9-20
64. Wójcicki J, Hinek A, Jaworska M, Samochowiec L. The effect of colchicine on the development of experimental atherosclerosis in rabbits. Pol J Pharmacol and Pharm. 1986 ; 38 (4). 343-348
65. Spagnoli LG, Orlandi A, Santeusanio G. Foam cells of the rabbit atherosclerotic plaque arrested in metaphase by colchicine show a macrophage phenotype. Atherosclerosis. 1991 ; 88 (1). 87-92
66. Bauriedel G. Growth-inhibiting effect of colchicine on cultured vascular wall myocytes from arteriosclerotic lesions. Z Kardiol. 1992 ; 81 (2). 92-98
67. Lagunoff D, Chi EY. Effect of colchicine on rat mast cells. J Cell Biol. 1976 ; 71 (1). 182-195
68. Perico N, Ostermann D, Bontempeill M, et al. Colchicine interferes with L-selectin and leukocyte function-associated antigen-1 expression on human T lymphocytes and inhibits T cell activation. J Am Soc Nephrol. 1996 ; 7 (4). 594-601
69. Ercolani L, Schulte WE. Metabolic and morphologic effects of colchicine on human T-lymphocyte expression of Fc mu and Fc gamma receptors. Cell Immunol. 1983 ; 77 (2). 222-232
70. Bauriedel G, Heimerl J, Beinert T, Welsch U, Höfling B. Colchicine antagonizes the activity of human smooth muscle cells cultivated from arteriosclerotic lesions after atherectomy. Coron Artery Dis. 1994 ; 5 (6). 531-539
71. Salai M, Segal E, Cohen I, et al. The inhibitory effects of colchicine on cell proliferation and mineralisation in culture. J Bone Joint Surg Br. 2001 ; 83 (6). 912-915
72. Simsek B, Islek I, Simsek T, Kucukoduk S, Cengiz K. Regression of nephrotic syndrome due to amyloidosis secondary to familial Mediterranean fever following colchicine treatment. Nephrol Dial Transplant. 2000 ; 15 (2). 281-282
73. Schlesinger N, Thiele RG. The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis. 2010 ; 69 (11). 1907-1912
74. Sari I, Yuksel A, Kozaci D, et al. The effect of regular colchicine treatment on biomarkers related with vascular injury in newly diagnosed patients with familial mediterranean fever. Inflammation. 2012 ; 35 (3). 1191-1197
75. Langevitz P, Livneh A, Neumann L, et al. Prevalence of ischemic heart disease in patients with familial Mediterranean fever. Isr Med Assoc J. 2001 ; 3 (1). 9-12
76. Crittenden DB, Lehmann RA, Schneck L, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012 ; 39 (7). 1458-1464
77. Nidorf SM, Thompson PL. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol. 2007 ; 99 (6). 805-807
78. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson LP. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013 ; 61 (4). 404-410
79. Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded end-point (PROBE) study. a novel design for intervention trials. prospective randomized open blinded end-point. Blood Press. 1992 ; 1 (2). 113-119
80. Peters R, Lehman TJA, Schwabe AD. Colchicine use for familial mediterranean fever observations associated with long-term treatment. West J Med. 1983 ; 138 (1). 43-46
81. Padeh S, Gerstein M, Berkun Y. Colchicine is a safe drug in children with familial Mediterranean fever. J Pediatr. 2012 ; 161 (6). 1142-1146
82. Wason S, Faulkner RD, Davis MW. Are dosing adjustments required for colchicine in the elderly compared with younger patients?. Adv Ther. 2012 ; 29 (6). 551-561
83. Diav-Citrin O, Shechtman S, Schwartz V, et al. Pregnancy outcome after in utero exposure to colchicine. Am J Obstet Gynecol. 2010 ; 203 (2). e1 - e6
84. Choi SSL, Chan KF, Ng HK, Mak WP. Colchicine-induced myopathy and neuropathy. Hong Kong Med J. 1999 ; 5 (2). 204-207
85. Malkinson FD, Lynfield YL. Colchicine alopecia. J Invest Dermatol. 1959 ; 33: 371-384
86. Ben-Chetrit E. Azoospermia in familial Mediterranean fever patients: the role of colchicine and amyloidosis. Ann Rheum Dis. 1998 ; 57 (4). 259-260
87. Yilmaz R, Ozer S, Ozyurt H, Erkorkmaz U. Serum Vitamin B12 status in children with familial mediterranean fever receiving colchicine treatment. HKJ Paediatr. 2011 ; 16: 3-8
88. Ben-Chetrit E, Navon P. Colchicine-induced leukopenia in a patient with familial Mediterranean fever: the cause and a possible approach. Clin Exp Rheumatol. 2003 ; 21 (4 suppl 30). S38 - S40
89. Alayli G, Cengiz K, Cantürk F, Durmuş D, Akyol Y, Menekşe EB. Acute myopathy in a patient with concomitant use of pravastatin and colchicine. Ann Pharmacother. 2005 ; 39 (7-8). 1358-1361
90. Imazio M, Brucato A, Trinchero R, Spodick D, Adler Y. Colchicine for pericarditis: hype or hope?. Eur Heart J. 2009 ; 30 (5). 532-539
91. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2009/022352s000-MedR. pdf. 58. Accessed May 2013.
92. http://livertox.nih.gov/Colchicine.htm. Accessed May 2013.
93. US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. http://www.fda.gov/ Drugs/DevelopmentApprovalProcess/DevelopmentResources/D. Accessed May 2013.
94. Bismuth C, Gaultier M, Conso F. Medullary aplasia after acute colchicine poisoning. 20 cases [in French]. Nouv Presse Med. 1977 ; 6 (19). 1625-1629
95. Chappey ON, Niel E, Wautier JL, et al. Colchicine disposition in human leukocytes after single and multiple oral administration. Clin Pharmacol Ther. 1993 ; 54 (4). 360-367
96. Lachmann HJ, Lowe P, Felix SD, et al. vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med. 2009 ; 206 (5). 1029-1036
97. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009 ; 360 (23). 2416-2425
98. Alten R, Gomez-Reino J, Durez P, et al. Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study. BMC Musculoskelet Disord. 2011 ; 12: 153
99. Ruperto N, Hermine MPH, Brunner I. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012 ; 367 (25). 2396-2406
100. Schlesinger N. Canakinumab in gout. Expert Opin Biol Ther. 2012 ; 12 (9). 1265-1275
101. Ilaris Prescribing Information web sitehttp://www.pharma.us.novartis.com/ cs/www.pharma.us.novartis.com/product/pi/pdf/ilaris.pdf. Accessed May 2013.
102. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). Am Heart J. 2011 ; 162 (4). 597-605
103. Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012 ; 71 (11). 1839-1848
104. http://www.medscape.com/viewarticle/745076. Accessed May 2013.
105. Laliberte RE, Eggler J, Gabel CA. ATP treatment of human monocytes promotes caspase-1 maturation and externalization. J Biol Chem. 1999 ; 274 (52). 36944-36951
106. Terkeltaub R, Zachariae C, Santoro D, Martin J, Peveri P, Matsushima K. Monocyte-derived neutrophil chemotactic factor/interleukin-8 is a potential mediator of crystal-induced inflammation. Arthritis Rheum. 1991 ; 34 (7). 894-903